Publications by authors named "Stuessi G"
Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal disorders caused by sequential accumulation of somatic driver mutations in hematopoietic stem and progenitor cells (HSPCs). MDS is characterized by ineffective hematopoiesis with cytopenia, dysplasia, inflammation, and a variable risk of transformation into secondary acute myeloid leukemia. The advent of next-generation sequencing has revolutionized our understanding of the genetic basis of the disease.
View Article and Find Full Text PDFAn amendment to this paper has been published and can be accessed via a link at the top of the paper.
View Article and Find Full Text PDFMore effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to intensive standard chemotherapy might improve their outcome. After establishing a safe lenalidomide, dose elderly patients with AML were randomly assigned in this randomized Phase 2 study (n = 222) to receive standard chemotherapy ("3 + 7") with or without lenalidomide at a dose of 20 mg/day 1-21.
View Article and Find Full Text PDFArticle Synopsis
- Myelodysplastic syndromes (MDS) are increasingly common among the elderly, presenting a growing challenge for healthcare systems, especially in Switzerland where a study was conducted from 2001 to 2012.
- The research revealed a 20% increase in annual MDS cases, though the incidence and mortality rates remained stable, indicating better diagnosis rather than higher risk among the aging population.
- The study also highlighted poor reporting on MDS subtype classifications, with only modest improvement, and found that younger patients had better 5-year survival rates compared to older patients, particularly following stem cell transplants; however, no significant survival benefits were identified for elderly patients receiving new treatments.